Can Wharton jelly derived or adipose tissue derived mesenchymal stem cell can be a treatment option for duchenne muscular dystrophy? Answers as transcriptomic aspect.

Autor:	Sun E; Histology and Embriology Department, Faculty of Medicine, İstinye University İstanbul, Turkey.; Center for Stem Cell and Tissue Engineering Research & Practice, İstinye University İstanbul, Turkey., Karaoz E; Histology and Embriology Department, Faculty of Medicine, İstinye University İstanbul, Turkey.; Center for Stem Cell and Tissue Engineering Research & Practice, İstinye University İstanbul, Turkey.; Center for Regenerative Medicine and Stem Cell Research and Manufacturing, Liv Hospital İstanbul, Turkey.
Jazyk:	angličtina
Zdroj:	American journal of stem cells [Am J Stem Cells] 2020 Aug 25; Vol. 9 (4), pp. 57-67. Date of Electronic Publication: 2020 Aug 25 (Print Publication: 2020).
Abstrakt:	Introduction: Mesenchymal stem cells (MSCs) are able to differentiate into several cell lineages including skeletal muscle. In addition to their differentiation capacities, they have the ability to transfer their content genomic information horizontally through their exosomes and fusion abilities, as we have shown in our previous clinic study on Duchenne Muscular Dystrophy (DMD) patients, dystrophin expression increased after MSC treatment. Therefore, this study aimed to compare the transcriptomic properties of Wharton's jelly derived (WJ-) MSC and Adipose tissue (AT-) derived MSC, which are the two most preferred sources in MSC treatments applied in DMD. Methods: Both MSC cell lines obtained from ATCC (PCS-500-010; PCS-500-011) were characterized by flow cytometry then WJ-MSC and AT-MSC cell lines were sequenced via RNA-SEQ. R language was used to obtain the differentially expressed genes (DEGs) and differentially expressed miRNAs, respectively. Additionally, in order to support the results of our study, a gene expression profile data set of DMD patients (GSE1004) were acquired from Gene Expression Omnibus (GEO) database. Results: Here, we demonstrated that activated WNT signaling and downregulated TGF-β pathways under the control of decreased mir-24 which are involved in myogenic differentiation are differentially expressed in WJ-MSC. We have shown that the expression of mir-199a-5p, which is known to increase in exosomes of DMD patients, is less in WJ-MSC. Additionally, we have shown activated PI3K/Akt pathway, which is controlling mitochondria transfer via Tunnelling Nanotube as a new perspective in cellular therapies in myodegenerative diseases, in WJ-MSC more than in AT-MSCs. Conclusion: Summing up, WJ-MSC, which we recommend as an appropriate source candidate due to its immune-regulation properties, stands forward as a preferable source in the cellular treatment of DMD patients due to its transcriptomic aspect. Competing Interests: None. (AJSC Copyright © 2020.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu